News Center
News Center
Disseminate company news and understand industry trends
Major Pharma Players Forge Alliance for AI-Driven Drug Discovery, Announcement Expected in Early Q3

Major Pharma Players Forge Alliance for AI-Driven Drug Discovery, Announcement Expected in Early Q3

Industry reports in July 2025 indicate that several leading pharmaceutical companies are finalizing a strategic alliance to create a shared AI platform for accelerating small molecule drug discovery. A formal announcement of this collaborative initiative is expected in early Q3 2025.

16

2025

/

10

Japan's MHLW Proposes New Guidelines to Accelerate Review of Complex Generic Drugs

Japan's MHLW Proposes New Guidelines to Accelerate Review of Complex Generic Drugs

In July 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) announced a draft guideline aimed at streamlining the approval process for complex generics, such as transdermal patches and inhalers. The move is designed to enhance market competition and ensure a stable supply of affordable complex medications.

16

2025

/

10

First Generic Versions of Popular GLP-1 Agonist Expected to Launch in Q3 2025 Following Patent Expiry

First Generic Versions of Popular GLP-1 Agonist Expected to Launch in Q3 2025 Following Patent Expiry

With a key patent expiring in August 2025, several generic drug manufacturers have received tentative FDA approval for their versions of a blockbuster GLP-1 receptor agonist. This is expected to significantly increase patient access to this class of diabetes and weight-management drugs starting in September.

16

2025

/

10

Positive Phase III Trial Results for Novel Alzheimer's Drug Lecanemab-Prodrome to be Presented at ECNP

Positive Phase III Trial Results for Novel Alzheimer's Drug Lecanemab-Prodrome to be Presented at ECNP

Full positive results from the Phase III clinical trial of "Lecanemab-Prodrome," targeting early-stage Alzheimer's disease, are scheduled for presentation at the European College of Neuropsychopharmacology (ECNP) Congress in late September 2025. The data is anticipated to show significant slowing of cognitive decline in prodromal patients.

16

2025

/

10

CPhI Worldwide 2025 to Take Place in Frankfurt, Highlighting Pharma Innovation and Global Supply Chain

CPhI Worldwide 2025 to Take Place in Frankfurt, Highlighting Pharma Innovation and Global Supply Chain

The prestigious CPhI Worldwide pharmaceutical exhibition is scheduled to be held in Frankfurt, Germany, from October 28 to 30, 2025. As the premier global event for the pharma industry, it will showcase the latest innovations in drug ingredients, manufacturing, and technology, while addressing critical issues of supply chain stability and sustainability.

16

2025

/

10

The 93rd API China Concludes Successfully in Chongqing, Driving Western China Pharma Development

The 93rd API China Concludes Successfully in Chongqing, Driving Western China Pharma Development

The 93rd API China (International Exhibition for Ingredients, Excipients, and Custom Manufacturing) concluded successfully at the Chongqing International Expo Center from November 12 to 14, 2025. As the premier event in Asia for the pharmaceutical ingredients industry, it served as a comprehensive platform showcasing the entire supply chain, from APIs and excipients to packaging and machinery. The event facilitated crucial connections and discussions on navigating the evolving pharmaceutical landscape in Western China.

16

2025

/

10

Clinical trials are a crucial stage in the research and development of drugs/medical devices and an important means of improving the development level of medical science and technology.

Clinical trials are a crucial stage in the research and development of drugs/medical devices and an important means of improving the development level of medical science and technology.

Clinical trials are a crucial stage in the drug/medical device development process and an important means of improving the development level of medical science and technology. How to achieve standardized management of clinical research, simplify research procedures, enable researchers to better implement standard operating procedures, improve research quality and level, ensure the accuracy and reliability of experimental results, and thus effectively shorten the new drug development cycle and accelerate the drug registration process has become the key for new drug research organizations to gain a foothold in the market and defeat their competitors.

21

2020

/

08

China will attempt to establish a long-term mechanism for the popularization of traditional Chinese medicine culture.

China will attempt to establish a long-term mechanism for the popularization of traditional Chinese medicine culture.

The National Administration of Traditional Chinese Medicine (NATCM) held a press conference in Beijing on the 13th, announcing that the first "Traditional Chinese Medicine and Chinese Materia Medica Go to China - Cultural Science Popularization Publicity Week" event will be launched in Beijing soon. Officials at the press conference stated that China will attempt to establish a long-term mechanism for the popularization of traditional Chinese medicine culture.

21

2020

/

08

< 12 >
Wanzhen Pharmaceutical

Our company is committed to the development and research of medical technology, closely cooperating with key laboratories of surrounding universities, using many years of market resources, striving to improve the independent innovation ability of enterprises, keeping up with the development trend of the international pharmaceutical market, and constantly providing source of power for the development of enterprises.

Contact Information

Tel

025-84676418、025-84676428

Email

wll@jswz-pharm.com

Address

D6-1104, Jiangsu Life Science and Technology Innovation Park, No. 9 Weidi Road, Qixia District, Nanjing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

025-84676418
025-84676428
wll@jswz-pharm.com
TOP

Copyright © 2025 Jiangsu Wanzhen Pharmaceutical Technology Co., Ltd.

Powered by:300.cn | SEO